Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, ≥ 6 years of age at Screening with a clinical diagnosis of LCA and a molecular diagnosis of homozygosity or compound heterozygosity for the CEP290 p.Cys998X mutation.~* Best-corrected visual acuity greater than or equal to light perception in both eyes and equal to or worse than LogMAR +1.0 (Snellen notation 20/200) in the worse eye and equal to or worse than LogMAR +0.7 (Snellen notation 20/100) in the contralateral eye.~* Detectable outer nuclear layer (ONL) in the area of the macula.~* An electroretinogram (ERG) result consistent with LCA.~* Clear ocular media and adequate pupillary dilation to permit good quality retinal imaging.~Exclusion Criteria:~* Syndromic disease.~* Pregnant or breast-feeding female.~* Any clinically significant cardiac disease or defect.~* One or more coagulation parameters outside of the normal range.~* Any ocular disease or condition that could compromise treatment safety, visual acuity or interfere with assessment of efficacy and safety.~* Prior receipt of intraocular surgery or intravitreal injection within 3 months prior to study start or planned intraocular surgery or procedure during the course of the study.~* Use of any investigational drug or device within 90 days or 5 half-lives of Day 1, whichever is longer, or plans to participate in another study of a drug or device during the PQ-110-001 study period.~* Any prior receipt of genetic therapy for LCA

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QR-110 (Type: EXPERIMENTAL): Administered every 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).